PLoS ONE (Jan 2020)

Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium.

  • Bastian Neesgaard,
  • Amanda Mocroft,
  • Robert Zangerle,
  • Ferdinand Wit,
  • Fiona Lampe,
  • Huldrych F Günthard,
  • Coca Necsoi,
  • Matthew Law,
  • Cristina Mussini,
  • Antonella Castagna,
  • Antonella d'Arminio Monforte,
  • Christian Pradier,
  • Nikoloz Chkhartisvilli,
  • Juliana Reyes-Uruena,
  • Jörg Janne Vehreschild,
  • Jan-Christian Wasmuth,
  • Anders Sönnerborg,
  • Christoph Stephan,
  • Lauren Greenberg,
  • Josep M Llibre,
  • Alain Volny-Anne,
  • Lars Peters,
  • Annegret Pelchen-Matthews,
  • Vani Vannappagari,
  • Joel Gallant,
  • Armin Rieger,
  • Mike Youle,
  • Dominique Braun,
  • Stephane De Wit,
  • Kathy Petoumenos,
  • Vanni Borghi,
  • Vincenzo Spagnuolo,
  • Tengiz Tsertsvadze,
  • Jens Lundgren,
  • Lene Ryom,
  • RESPOND study group

DOI
https://doi.org/10.1371/journal.pone.0243625
Journal volume & issue
Vol. 15, no. 12
p. e0243625

Abstract

Read online

ObjectivesTo compare virologic and immunologic outcomes of integrase inhibitor (INSTI)-containing, contemporary boosted protease inhibitor (PI/b)-containing and non-nucleotide reverse transcriptase inhibitor (NNRTI)-containing regimens in a real-life setting.MethodsUsing logistic regression, virologic and immunologic outcomes of INSTI use were compared to outcomes of PI/b or NNRTI treatment 12 months after treatment start or switch, for participants in the RESPOND cohort consortium. A composite treatment outcome (cTO) was used, defining success as viral load (VL) ResultsBetween January 2012 and January 2019, 13,703 (33.0% ART-naïve) individuals were included, of whom 7,147 started/switched to a regimen with an INSTI, 3,102 to a PI/b and 3,454 to an NNRTI-containing regimen. The main reason for cTO failure in all treatment groups were changes in ART regimen. Compared to INSTIs, the adjusted odds ratio (aOR) of cTO success was significantly lower for PI/b (0.74 [95% confidence interval, CI 0.67-0.82], p ConclusionIn this large analysis of a real-world population, cTO and on-treatment success were similar between INSTIs and NNRTIs, but lower for PI/b, though residual confounding cannot be fully excluded. Obtaining favorable immunologic outcomes were more likely for INSTIs than the other drug classes.